Document is current

Article History

Received: 14 January 2026

Accepted: 24 April 2026

First Online: 11 May 2026

Declarations

:

: We received ethics approval from Monash Health to conduct and publish this study (Ethics committee reference: 14262 A).Informed consent was obtained from all subjects involved in the study.

: Not applicable.

: Rangi Kandane-Rathnayake (RKR): has received grants from BMS, GSK, Janssen and Novartis Rachel Koelmeyer (RK): none Shereen Oon (SO): has received speaker fees from Astra Zeneca and The Limbic Maureen Rischmueller (MR): has received research grants from AbbVie, Amgen, Argenx, AstraZeneca, BMS, GSK, Horizon, J&J, LG Chem, Novartis, UCB; and consultant/speaker honoraria from AbbVie, Amgen, Boehringer Ingelheim, J&J, Novartis, Pfizer, Recordati, Sandoz, UCB. Yumi Oh (YO): none Sean O’Neill (SO’N): none Geraldine Hassett (GH): none Sachin Khetan (SK): none Ted Tsai (TT): none Fiona Goldblatt (FG): none Ashleigh Hennessey (AH): none Dwarakanathan Ranganathan (DR): has received unrestricted Grant for POEMSLUN study from Novartis, Australia Astrid Jullion (AJ): is employed by Novartis Tamas Shisha (TS): is employed by Novartis Peter Gergely (PG): is employed by Novartis Mandana Nikpour (MN): has received an Investigator Grant from the National Health and Medical Research Council of Australia (NHMRC GNT1176538), research grants from Boehringer Ingelheim and Janssen, consulting fees from AstraZeneca and GSK; honoraria for presentations from AstraZeneca, Boehringer Ingelheim and GSK, and support for conference attendance from Boehringer Ingelheim. Eric Morand (EM): has received consulting fees from AbbVie, AstraZeneca, Biogen, Bristol Myers Squibb, Genentech, Gilead, Janssen, Novartis, and EMD Serono. Alberta Hoi: has received a research grant from AstraZeneca, consulting fees from EUSA Pharma (UK), GSK and UCB Australia, and speaker fees/honoraria from AbbVie, Eli Lilly, Janssen, Limbic, Moose Republic and Novartis.